10 Jazz Pharmaceuticals plc Analyst Ratings, Earnings, Dividends and Insider Trades | $JAZZ | NASDAQ:JAZZ | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact Jazz Pharmaceuticals plc Company Profile (NASDAQ:JAZZ) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 4 Hold Rating(s), 9 Buy Rating(s)Consensus Rating:Buy (Score: 2.69)Consensus Price Target: $172.94 (11.40% upside) Analysts' Ratings History for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare3/7/2014BarclaysInitiated CoverageOverweight$200.00View 2/28/2014ZacksReiterated RatingNeutral -> Neutral$175.00View 2/26/2014Cowen and CompanyBoost Price Target$160.00 -> $190.00View 2/26/2014Brean CapitalBoost Price Target$171.00 -> $207.00View 2/26/2014Leerink SwannBoost Price Target$159.00 -> $189.00View 2/26/2014UBS AGBoost Price TargetBuy$164.00 -> $195.00View 2/26/2014Citigroup Inc.Boost Price TargetBuy$132.00 -> $195.00View 2/26/2014Stifel NicolausBoost Price TargetBuy$145.00 -> $195.00View 2/26/2014Cantor FitzgeraldDowngradeBuy -> Hold$170.00 -> $182.00View 2/26/2014Piper JaffrayBoost Price TargetOverweight$159.00 -> $201.00View 2/26/2014GuggenheimBoost Price TargetBuy$140.00 -> $210.00View 1/24/2014ZacksReiterated RatingNeutral -> Neutral$167.00View 1/15/2014ZacksDowngradeOutperform -> Neutral$148.80View 1/14/2014UBS AGBoost Price TargetBuy$130.00 -> $164.00View 1/14/2014R. F. LaffertyDowngradeBuy -> Neutral$140.00View 12/20/2013Brean CapitalBoost Price Target$171.00View 12/16/2013Goldman SachsDowngradeBuy -> Neutral$105.00 -> $123.00View 12/6/2013UBS AGBoost Price TargetBuy -> Buy$110.00 -> $130.00View 12/4/2013Cantor FitzgeraldBoost Price Target$145.00View 11/25/2013BarclaysBoost Price TargetOverweight$112.00 -> $130.00View 11/25/2013FBR Capital MarketsReiterated RatingOutperform -> Outperform$105.00 -> $198.00View 11/13/2013R. F. LaffertyBoost Price TargetBuy$102.00 -> $118.00View 11/8/2013ZacksUpgradeNeutral -> Outperform$96.00View 11/6/2013Stifel NicolausBoost Price TargetBuy$85.00 -> $100.00View 11/6/2013Cantor FitzgeraldBoost Price TargetBuy$97.00 -> $106.00View 11/6/2013Brean CapitalBoost Price TargetBuy$93.00 -> $119.00View 11/6/2013UBS AGBoost Price TargetBuy$98.00 -> $110.00View 10/30/2013FBR & Co.Initiated CoverageOutperformView 10/30/2013FBR Capital MarketsInitiated CoverageOutperform$105.00View 10/8/2013ZacksDowngradeOutperform -> Neutral$95.00View 9/19/2013GuggenheimBoost Price TargetBuy$90.00 -> $105.00View 9/19/2013Cowen and CompanyBoost Price TargetOutperform$85.00 -> $120.00View 9/17/2013Goldman SachsInitiated CoverageBuyView 9/13/2013Lazard Capital MarketsReiterated RatingBuy$93.00View 9/13/2013UBS AGBoost Price TargetBuy$87.00 -> $98.00View 8/22/2013R. F. LaffertyInitiated CoverageBuy$102.00View 8/7/2013Lazard Capital MarketsBoost Price TargetBuy$87.00 -> $93.00View 8/7/2013JMP SecuritiesBoost Price Target$66.00 -> $74.00View 8/7/2013GuggenheimBoost Price TargetBuy$81.00 -> $90.00View 8/7/2013BarclaysBoost Price TargetOverweight$70.00 -> $85.00View 8/7/2013Stifel NicolausReiterated RatingBuy$80.00 -> $85.00View 8/7/2013UBS AGBoost Price TargetBuy$80.00 -> $87.00View 8/7/2013Cantor FitzgeraldBoost Price TargetBuy$86.00 -> $97.00View 7/9/2013Cantor FitzgeraldReiterated RatingBuyView 6/21/2013Brean CapitalBoost Price Target$88.00 -> $93.00View 6/20/2013Stifel NicolausReiterated RatingBuy$80.00View 6/20/2013GuggenheimBoost Price TargetBuy$69.00 -> $81.00View 5/31/2013Cantor FitzgeraldReiterated RatingBuyView 5/31/2013Stifel NicolausInitiated CoverageBuy -> Buy$80.00View 5/22/2013GuggenheimReiterated RatingBuy$69.00View 5/8/2013Cantor FitzgeraldReiterated RatingBuy$86.00View 4/15/2013JMP SecuritiesInitiated CoverageOutperformView 3/28/2013JMP SecuritiesInitiated CoverageOutperform$66.00View 3/12/2013Citigroup Inc.Boost Price Target$75.00View 3/11/2013Cantor FitzgeraldInitiated CoverageBuy$86.00View 2/27/2013Piper JaffrayBoost Price Target$69.00View 2/27/2013WallachBeth CapitalBoost Price TargetBuy$63.00 -> $70.00View 2/27/2013UBS AGBoost Price TargetBuy$64.00 -> $67.00View 2/27/2013Brean CapitalBoost Price TargetBuy$81.00 -> $88.00View 2/25/2013Bank of AmericaInitiated CoverageBuy$74.00View 2/4/2013Lazard Ltd.Reiterated RatingBuy$87.00View 1/18/2013Lazard Ltd.Boost Price TargetBuy$76.00 -> $87.00View 12/14/2012UBS AGReiterated RatingBuy$64.00View 12/11/2012Citigroup Inc.Reiterated RatingBuy$70.00View 12/4/2012Brean CapitalReiterated RatingBuy$81.00View 11/29/2012UBS AGInitiated CoverageBuy$64.00View 11/27/2012Citigroup Inc.Initiated CoverageBuy$70.00View 9/28/2012OppenheimerReiterated RatingOutperform -> OutperformView 9/27/2012Brean CapitalInitiated CoverageBuy$81.00View 9/20/2012Leerink SwannReiterated RatingOutperformView 9/18/2012BarclaysReiterated RatingOverweightView 9/18/2012GuggenheimInitiated CoverageBuy$60.00View 9/11/2012Leerink SwannReiterated RatingOutperformView 9/6/2012Cowen and CompanyInitiated CoverageNeutral -> NeutralView 8/27/2012WallachBeth CapitalInitiated CoverageBuy$63.00View 8/8/2012Piper JaffrayBoost Price Target$64.00 -> $68.00View 8/8/2012Lazard Ltd.Raise EstimatesBuy$76.00View 8/7/2012Leerink SwannReiterated RatingOutperform$68.00View 7/12/2012Lazard Ltd.Reiterated RatingBuyView 7/12/2012Lazard Ltd.Boost Price Target$63.00 -> $75.00View 6/21/2012BarclaysInitiated CoverageOverweightView 5/23/2012Credit SuisseInitiated CoverageOutperform$65.00View 5/22/2012OppenheimerInitiated CoverageOutperform$66.00View 5/9/2012AurigaReiterated RatingBuyView 5/2/2012MizuhoBoost Price TargetBuy$62.00 -> $75.00View 4/20/2012AurigaReiterated RatingBuyView 4/13/2012Leerink SwannInitiated CoverageOutperformView 4/10/2012Citigroup Inc.Initiated CoverageBuy$60.00View 3/21/2012AurigaReiterated RatingBuy$150.00View (Data available from 3/8/2012 forward) Earnings History for Jazz Pharmaceuticals plc (NASDAQ:JAZZ)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare2/25/2014Q413$1.78$1.72$238.12 million$235.80 millionViewListenView 11/5/2013Q313$1.67$1.78$227.38 million$232.20 millionViewListenView 8/6/2013Q2 2013$1.52$1.43$208.71 million$208.30 millionViewListenView 5/7/2013Q1 2013$1.35$1.37$189.92 million$196.20 millionViewListenView 2/26/2013Q4 2012$1.41$1.53$183.80 million$183.70 millionViewListenView 11/8/2012Q312$1.31$1.29$178.57 million$175.50 millionViewN/AView 8/7/2012$1.05$1.09ViewN/AView 5/8/2012$0.90$0.91ViewN/AView 11/1/2011$0.89$0.94ViewN/AView 7/28/2011$0.67$0.82ViewN/AView 5/3/2011$0.57$0.59ViewN/AView 3/7/2011$0.60$0.63ViewN/AView (Data available from 1/1/2011 forward) Dividend History for Jazz Pharmaceuticals plc (NASDAQ:JAZZ)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for Jazz Pharmaceuticals plc (NASDAQ:JAZZ)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare3/6/2014Fintan KeeganEVPSell4,640$159.90$741,936.00View 3/4/2014Seamus MulliganDirectorSell550,000$156.25$85,937,500.00View 3/3/2014Patrick EnrightDirectorSell559,628$152.39$85,281,710.92View (Data available from 1/1/2013 forward) About Jazz Pharmaceuticals plc Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder. Its marketed products and late-stage product candidate are Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) Extended-Release Capsules and JZP-6 (sodium oxybate). Its other product candidates in clinical development are oral tablet forms of sodium oxybate; JZP-8 (intranasal clonazepam); JZP-4 (elpetrigine), and JZP-7 (ropinirole gel). Headlines: (2/25) Jazz Pharmaceuticals Announces Management Change (2/26) Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March (2/25) Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2013 Financial Results (2/21) Jazz Pharmaceuticals plc Completes Tender Offer For Gentium S.p.A. Shares (2/25) Jazz Pharmaceuticals Q4 Results Miss Estimates, Guides 2014 EPS In Line (2/11) Jazz Pharmaceuticals Announces U.S. Commercial Availability Of Versacloz™ (clozapine, USP) Oral Suspension (2/11) Jazz Pharmaceuticals to Report 2013 Fourth Quarter and Full Year Financial Results on February 25, 2014 (2/26) Press Release Industry, Sector and Symbol: Sector: Healthcare Industry: Pharmaceuticals Sub-Industry: Pharmaceuticals Exchange: NASDAQ Symbol: JAZZ CUSIP: G5087110 Key Metrics: Previous Close: $151.4850 Day Moving Average: $157.114200 Day Moving Average: $116.008 P/E Ratio: 43.16P/E Growth: 0.92Market Cap: $9.014BCurrent Quarter EPS Consensus Estimate: $8.27 EPS Additional Links: View JAZZ on Google FinanceView JAZZ on Yahoo FinanceView JAZZ's Company Profile on ReutersSearch for Jazz Pharmaceuticals plc on Google Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Chart for Saturday, March, 8, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.